New Zealand markets close in 21 minutes
  • NZX 50

    11,188.52
    -69.76 (-0.62%)
     
  • NZD/USD

    0.6340
    +0.0044 (+0.70%)
     
  • NZD/EUR

    0.6035
    +0.0024 (+0.40%)
     
  • ALL ORDS

    7,307.50
    -119.10 (-1.60%)
     
  • ASX 200

    7,065.50
    -117.20 (-1.63%)
     
  • OIL

    110.65
    +1.06 (+0.97%)
     
  • GOLD

    1,813.80
    -2.10 (-0.12%)
     
  • NASDAQ

    11,928.31
    -635.79 (-5.06%)
     
  • FTSE

    7,438.09
    -80.26 (-1.07%)
     
  • Dow Jones

    31,490.07
    -1,164.52 (-3.57%)
     
  • DAX

    14,007.76
    -178.18 (-1.26%)
     
  • Hang Seng

    20,179.30
    -464.98 (-2.25%)
     
  • NIKKEI 225

    26,424.15
    -487.05 (-1.81%)
     
  • NZD/JPY

    81.6420
    +0.9180 (+1.14%)
     

Seres Therapeutics to Present at 40th Annual J.P. Morgan Healthcare Conference

·1-min read

CAMBRIDGE, Mass., January 04, 2022--(BUSINESS WIRE)--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that it will present a corporate overview at the 40th Annual J.P. Morgan Healthcare Conference on Thursday, January 13 at 8:15 a.m. ET.

A live audio webcast of the presentation will be available under the "Investors and News" section of Seres’ website. A replay of the presentation will become available approximately one hour after the event and will be archived for approximately 21 days.

About Seres Therapeutics
Seres Therapeutics, Inc., (Nasdaq: MCRB) is a leading microbiome therapeutics company developing a novel class of multifunctional bacterial consortia that are designed to functionally interact with host cells and tissues to treat disease. Seres’ SER-109 program achieved the first-ever positive pivotal clinical results for a targeted microbiome drug candidate and has obtained Breakthrough Therapy and Orphan Drug designations from the FDA. The SER-109 program is being advanced for the treatment of recurrent C. difficile infection and has potential to become a first-in-class FDA-approved microbiome therapeutic. Seres is evaluating SER-301 in a Phase 1b study in patients with ulcerative colitis and SER-155 in a Phase 1b study to address gastrointestinal infections, bacteremia and graft-versus-host disease. For more information, please visit www.serestherapeutics.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220104005194/en/

Contacts

PR
Kristin Ainsworth
kainsworth@serestherapeutics.com

IR
Carlo Tanzi, Ph.D.
ctanzi@serestherapeutics.com

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting